Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

European approval for Parsabiv to treat secondary hyperparathyroidism in hemodialysis patients

Nov. 14, 2016

Glucagon/thyroid hormone conjugate improves experimental metabolic conditions

Nov. 11, 2016

PhaseRx reports positive results from animal study of PRX-OTC

Nov. 9, 2016

Eloxx Pharmaceuticals reports orphan drug designations for ELX-02 from both FDA and EMA

Nov. 9, 2016

The Medicines Company discontinues development of MDCO-216

Nov. 8, 2016

Researchers report new T2D risk loci in Jordan subpopulations

Nov. 7, 2016

Zucara Therapeutics receives investment from Canadian partners

Nov. 7, 2016

FDA awards orphan drug designation to Amryt's AP-102

Nov. 7, 2016

Investigators identify novel causative mutations in mucopolysaccharidosis type IV patients

Nov. 3, 2016

Pfizer discontinues bococizumab global development program

Nov. 2, 2016

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...